Phoenix Dance: The Eldest Daughter's Physician Consort Shocks the World

Chapter 359 Production and Distribution Challenges and Solutions to Approval Differences

With the exciting news of the successful development of a drug to treat a novel disease, the "Medical New Alliance" was filled with jubilation. However, before Su Yao and her team could even properly celebrate, they immediately plunged into a new challenge—how to rapidly produce and distribute the drug globally, and how to address the differences in drug approval standards across different countries.

“Miss Su, although we have developed the drug, achieving global supply will be fraught with difficulties.” The member in charge of production said with a frown and a worried expression. “First of all, there is the issue of production scale. The existing production lines are far from meeting the needs of patients around the world. Expanding production scale requires a lot of funds and equipment, which cannot be solved in the short term.”

Su Yao pondered for a moment and said, "Regarding funding, we can request support from the imperial court, and also seek international investment and assistance. As for equipment procurement, we should contact major suppliers to see if they can expedite the customization process. In addition, we need to formulate a detailed plan for expanding production as soon as possible, rationally arrange the production process, and improve production efficiency."

At this point, the member in charge of delivery also raised a problem: "Ms. Su, even if we produce enough medicine, delivery is a big problem. The traffic conditions and logistics infrastructure vary greatly around the world, and some remote areas are simply difficult to reach. Moreover, it is difficult to guarantee the preservation conditions of the medicine during transportation."

Su Yao nodded. "We need to collaborate with internationally renowned logistics companies to develop specialized delivery plans. For remote areas, we can consider partnering with local medical institutions or charitable organizations to deliver the medicines via a relay system. At the same time, we will develop special medicine preservation equipment to ensure that the quality of the medicines is not affected during transportation."

Meanwhile, the differing approval standards for drugs in different countries have also created significant obstacles to the promotion efforts. "Ms. Su, we've submitted drug approval applications to several countries, but their approval processes are cumbersome, and their standards vary. Some countries require us to conduct additional clinical trials, while others have extremely strict testing requirements for drug components, which has greatly slowed down our promotion progress," the member in charge of international affairs said helplessly.

Su Yao sighed, "This is indeed a tricky problem. We need to set up a dedicated team to study the approval standards of various countries and prepare relevant materials according to their requirements. For countries that require additional clinical trials, we need to make arrangements as soon as possible and strive to obtain approval at an early date."

To resolve these issues, Su Yao went to the palace to discuss with Xiao Yichen, hoping the court could provide more support in terms of funding and policy. "Your Majesty," she said, "the drug has now been successfully developed, but it has encountered many difficulties in its global promotion, especially in terms of production and approval. We hope Your Majesty can lend a helping hand."

Xiao Yichen held Su Yao's hand and said gently, "Yao'er, don't worry, I will fully support you. The court will allocate special funds for drug production, and at the same time, we will communicate and coordinate with various countries to facilitate drug approval."

On the other hand, Su Yao organized the members of the "Medical Innovation Alliance" to work day and night. The production team worked overtime to plan the new production line and communicate with suppliers about equipment procurement; the distribution team repeatedly discussed distribution plans with logistics companies and tested drug storage equipment; and the team responsible for international affairs conducted in-depth research on the approval standards of various countries and prepared approval documents.

"You've all worked so hard. We've come this far, and we absolutely cannot give up because of these difficulties. As long as we work together, we will definitely be able to overcome all challenges," Su Yao encouraged everyone at the team meeting.

Under Su Yao's leadership, the members of the "Medical New Alliance" worked hard to meet the challenges in production, distribution, and approval. They had only one belief in their hearts: to enable more patients to use life-saving drugs as soon as possible.